Oskar Wysocki
Overview
Explore the profile of Oskar Wysocki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
40
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wysocka M, Wysocki O, Delmas M, Mutel V, Freitas A
J Biomed Inform
. 2024 Sep;
158:104724.
PMID: 39277154
Objective: The paper introduces a framework for the evaluation of the encoding of factual scientific knowledge, designed to streamline the manual evaluation process typically conducted by domain experts. Inferring over...
2.
Bykowska-Tumasz M, Wysocki O, Sikorska K
Travel Med Infect Dis
. 2023 Sep;
55:102642.
PMID: 37717797
Background: There is a lack of information about health problems after returning from tropical countries among travelers from Poland. The aim was to create characteristics of diseases imported to Poland...
3.
Wysocka M, Wysocki O, Zufferey M, Landers D, Freitas A
BMC Bioinformatics
. 2023 May;
24(1):198.
PMID: 37189058
Background: There is an increasing interest in the use of Deep Learning (DL) based methods as a supporting analytical framework in oncology. However, most direct applications of DL will deliver...
4.
Bogatu A, Wysocka M, Wysocki O, Butterworth H, Pillai M, Allison J, et al.
J Biomed Inform
. 2023 Apr;
142:104367.
PMID: 37105509
Cytokine release syndrome (CRS), also known as cytokine storm, is one of the most consequential adverse effects of chimeric antigen receptor therapies that have shown otherwise promising results in cancer...
5.
Wysocki O, Zhou C, Rogado J, Huddar P, Shotton R, Tivey A, et al.
Cancers (Basel)
. 2022 Aug;
14(16).
PMID: 36010932
Patients with cancer have been shown to have increased risk of COVID-19 severity. We previously built and validated the COVID-19 Risk in Oncology Evaluation Tool (CORONET) to predict the likely...
6.
Lee R, Wysocki O, Zhou C, Shotton R, Tivey A, Lever L, et al.
JCO Clin Cancer Inform
. 2022 May;
6:e2100177.
PMID: 35609228
Purpose: Patients with cancer are at increased risk of severe COVID-19 disease, but have heterogeneous presentations and outcomes. Decision-making tools for hospital admission, severity prediction, and increased monitoring for early...
7.
Burke H, Freeman A, ORegan P, Wysocki O, Freitas A, Dushianthan A, et al.
BMJ Open
. 2022 Feb;
12(2):e050331.
PMID: 35168965
Objectives: COVID-19 is a heterogeneous disease, and many reports have described variations in demographic, biochemical and clinical features at presentation influencing overall hospital mortality. However, there is little information regarding...
8.
Freeman A, Watson A, ORegan P, Wysocki O, Burke H, Freitas A, et al.
J Clin Virol
. 2021 Nov;
146:105031.
PMID: 34844145
Objectives: Dexamethasone has now been incorporated into the standard of care for COVID-19 hospital patients. However, larger intensive care unit studies have failed to show discernible improvements in mortality in...